

AS
cont

R_6 is selected from H, C_1 - C_6 alkyl, C_1 - C_6 alkoxy, $-C(O)CH_3$, phenyl, -O-phenyl, benzyl, -O-benzyl, the phenyl and benzyl rings of these groups being optionally substituted by from 1 to 3 substituents selected from halogen, C_1 - C_6 alkyl, C_1 - C_6 alkoxy, $-NO_2$, $-NH_2$, $-CN$, $-CF_3$, or $-OH$;

R_7 is selected from $-(CH_2)_n-COOH$, $-(CH_2)_n-N-(C_1-C_6 \text{ alkyl})_2$, $-(CH_2)_n-NH-(C_1-C_6 \text{ alkyl})$, $-CF_3$, C_1 - C_6 alkyl, C_3 - C_6 cycloalkyl, C_1 - C_6 alkoxy, $-NH-(C_1-C_6 \text{ alkyl})$, $-N-(C_1-C_6 \text{ alkyl})_2$, pyridinyl, thienyl, furyl, pyrrolyl, quinolyl, $(CH_2)_n$ phenyl, phenyl, -O-phenyl, benzyl, -O-benzyl, adamantyl, or morpholinyl, $-(CH_2)_n$ -phenyl-O-phenyl, $-(CH_2)_n$ -phenyl- CH_2 -phenyl, $-(CH_2)_n$ -O-phenyl- CH_2 -phenyl, $-(CH_2)_n$ -phenyl-(O- CH_2 -phenyl) $_2$, the rings of these groups being optionally substituted by from 1 to 3 substituents selected from halogen, C_1 - C_6 alkyl, C_1 - C_6 alkoxy, $-NH_2$, $-NO_2$, $-CF_3$, CO_2H , or $-OH$;

R_2 is selected from H, halogen, $-CF_3$, $-OH$, $-C_1$ - C_{10} alkyl, C_1 - C_{10} alkoxy, $-CHO$, $-CN$, $-NO_2$, $-NH_2$, $-NH-C_1-C_6 \text{ alkyl}$, $-N(C_1-C_6 \text{ alkyl})_2$, $-N-SO_2-C_1-C_6 \text{ alkyl}$, or $-SO_2-C_1-C_6 \text{ alkyl}$;

R_3 is selected from H, $-CF_3$, C_1 - C_6 lower alkyl, C_1 - C_6 lower alkoxy, C_3 - C_{10} cycloalkyl, $-C_1-C_6 \text{ alkyl}$, $-C_3-C_{10}$ cycloalkyl, $-CHO$, halogen, $(CH_2)_nC(O)NH_2$ or a moiety of the formula $-L^1-M^1$;

L^1 indicates a linking or bridging group of the formulae $-(CH_2)_n$ -, $-S$ -, $-O$ -, $-C(O)$ -, $-(CH_2)_n-C(O)$ -, $-(CH_2)_n-C(O)-(CH_2)_n$ -, $-(CH_2)_n-O-(CH_2)_n$ -, or $-(CH_2)_n-S-(CH_2)_n$ -, $C(O)C(O)X$, $-(CH_2)_n-N-(CH_2)_n$;

M¹ is selected from:

a) H, the group of C₁-C₆ lower alkyl, C₁-C₆ lower alkoxy, C₃-C₁₀ cycloalkyl, phenyl or benzyl, the cycloalkyl, phenyl or benzyl rings being optionally substituted by from 1 to 3 substituents selected from halogen, C₁-C₁₀ alkyl, C₁-C₁₀ alkoxy, -NO₂, -NH₂, -CN, or -CF₃; or


b) a five-membered heterocyclic ring containing one or two ring heteroatoms selected from N, S or O, the five-membered heterocyclic ring being optionally substituted by from 1 to 3 substituents selected from halogen, C₁-C₁₀ alkyl, C₁-C₁₀ alkoxy, -NO₂, -NH₂, -CN, or -CF₃; or

c) a six-membered heterocyclic ring containing one, two or three ring heteroatoms selected from N, S or O, the six-membered heterocyclic ring being optionally substituted by from 1 to 3 substituents selected from halogen, C₁-C₁₀ alkyl, C₁-C₁₀ alkoxy, -CHO, -NO₂, -NH₂, -CN, -CF₃ or -OH; or

d) a bicyclic ring moiety containing from 8 to 10 ring atoms and optionally containing from 1 to 3 ring heteroatoms selected from N, S or O, the bicyclic ring moiety being optionally substituted by from 1 to 3 substituents selected from halogen, C₁-C₁₀ alkyl, C₁-C₁₀ alkoxy, -CHO, -NO₂, -NH₂, -CN, -CF₃ or -OH;

R₄ is selected from the group of C₁-C₆ lower alkyl, C₁-C₆ lower alkoxy, -(CH₂)_n-C₃-C₆ cycloalkyl, -(CH₂)_n-S-(CH₂)₂-C₃-C₅ cycloalkyl, -(CH₂)_n-O-(CH₂)_n-C₃-C₅ cycloalkyl, or the groups of:

a) -(CH₂)_n-phenyl-O-phenyl, -(CH₂)_n-phenyl-CH₂-phenyl, -(CH₂)_n-O-phenyl-CH₂-phenyl, -(CH₂)_n-phenyl-(O-CH₂-phenyl)₂, or a moiety of the formulae:



wherein n is independently selected in each appearance as an integer from 0 to 3, Y is C₃-C₅ cycloalkyl, phenyl, benzyl, naphthyl, pyridinyl, quinolyl, furyl, thienyl or pyrrolyl; rings of these groups being optionally substituted by from 1 to 3 substituents selected from H, halogen, -CF₃, -OH, -C₁-C₆ alkyl, C₁-C₆ alkoxy, -NH₂, -NO₂ or a five membered heterocyclic ring containing one heteroatom selected from N, S, or O; or

b) a moiety of the formulae $-(CH_2)_n-A$, $-(CH_2)_n-S-A$, or $-(CH_2)_n-O-A$, wherein A is the moiety:









wherein

D is H, C₁-C₆ lower alkyl, C₁-C₆ lower alkoxy, or -CF₃;

B and C are independently selected from phenyl, pyridinyl, furyl, thienyl, pyrimidinyl or pyrrolyl groups, each optionally substituted by from 1 to 3, substituents selected from H, halogen, -CF₃, -OH, -C₁-C₆ alkyl, C₁-C₆ alkoxy, or -NO₂; or

c) a moiety of the formulae:





or

wherein Z is O or S and the phenyl and pyrimidinyl rings of each moiety are optionally and independently substituted by from 1 to 3 substituents selected from halogen, $-CF_3$, $-OH$, $-C_1$ - C_8 alkyl, C_1 - C_8 alkoxy, $-NH_2$ or $-NO_2$; or

d) a moiety of the formula $-L^2-M^2$, wherein:

L^2 indicates a linking or bridging group of the formulae $-(CH_2)_n-$, $-S-$, $-O-$, $-SO_2-$, $-C(O)-$, $-(CH_2)_n-C(O)-$, $-(CH_2)_n-C(O)-(CH_2)_n-$, $-(CH_2)_n-O-(CH_2)_n-$, or $-(CH_2)_n-S-(CH_2)_n-$, $-C(O)C(O)X$;

where X = O, N

M^2 is selected from the group of C_1 - C_8 lower alkyl, C_1 - C_8 lower alkoxy, C_3 - C_{10} cycloalkyl, phenyl or benzyl, the cycloalkyl, phenyl or benzyl rings being optionally substituted by from 1 to 3 substituents selected from halogen, C_1 - C_{10} alkyl, C_1 - C_{10} alkoxy, $-NO_2$, $-NH_2$, $-CN$, or $-CF_3$; or




i) a five-membered heterocyclic ring containing one or two ring heteroatoms selected from N, S or O, the five-membered heterocyclic ring being optionally substituted by from 1 to 3 substituents selected from halogen, C_1 - C_{10} alkyl, C_1 - C_{10} alkoxy, $-NO_2$, $-NH_2$, $-CN$, or $-CF_3$; or

ii) a six-membered heterocyclic ring containing one, two or three ring heteroatoms selected from N, S or O, the six-membered heterocyclic ring being optionally substituted by from 1 to 3 substituents selected from halogen, C₁-C₁₀ alkyl, C₁-C₁₀ alkoxy, -CHO, -NO₂, -NH₂, -CN, -CF₃ or -OH; or

iii) a bicyclic ring moiety containing from 8 to 10 ring atoms and optionally containing from 1 to 3 ring heteroatoms selected from N, S or O, the bicyclic ring moiety being optionally substituted by from 1 to 3 substituents selected from halogen, C₁-C₁₀ alkyl, C₁-C₁₀ alkoxy, -CHO, -NO₂, -NH₂, -CN, -CF₃ or -OH;

n is an integer from 0 to 3;

R₆ is selected from -COOH, -C(O)-COOH, -(CH₂)_n-C(O)-COOH, -(CH₂)_n-COOH, (CH₂)_n-CH=CH-COOH, -(CH₂)_n-tetrazole, -CH₂-phenyl-C(O)-benzothiazole, or




or a moiety selected from the formulae -L³-M³,

wherein L³ is a bridging or linking moiety selected from a chemical bond, -(CH₂)_n-, -S-, -O-, -SO₂-, -C(O)-, -(CH₂)_n-C(O)-, -(CH₂)_n-C(O)-(CH₂)_n-, -(CH₂)_n-O-(CH₂)_n-, -(CH₂)_n-S-(CH₂)_n-, -C(Z)-N(R₆)-, -C(Z)-N(R₆)-(CH₂)_n-, -C(O)-C(Z)-N(R₆)-, -C(O)-C(Z)-N(R₆)-(CH₂)_n-, -C(Z)-NH-


SO_2^- , $-\text{C}(\text{Z})\text{-NH-SO}_2\text{-(CH}_2)_n-$, $-(\text{CH}_2)_n\text{-S-(CH}_2)_n-$, $-(\text{CH}_2)_n\text{-SO-(CH}_2)_n-$, $-(\text{CH}_2)_n\text{-SO}_2\text{-(CH}_2)_n-$, or $-(\text{CH}_2)_n\text{-CH=CH-(CH}_2)_n\text{-O-}$;

M^3 is selected from the group of $-\text{COOH}$, $-(\text{CH}_2)_n\text{COOH}$, $-(\text{CH}_2)_n\text{C(O)-COOH}$, tetrazole,



where R_8 , R_9 or R_{10} can be attached anywhere in the cyclic or bicyclic system,
 n is an integer from 0 to 3;


R_8 , in each appearance, is independently selected from H , $-\text{COOH}$, $-(\text{CH}_2)_n\text{COOH}$, $-(\text{CH}_2)_n\text{C(O)-COOH}$, tetrazole, $-\text{C(O)-NH}_2$, $-(\text{CH}_2)_n\text{C(O)-NH}_2$,




n is an integer from 0 to 3;

R_9 is selected from H, halogen, $-CF_3$, $-OH$, $-COOH$, $-(CH_2)_n-COOH$, $-(CH_2)_n-C(O)-COOH$, $-C_1-C_6$ alkyl, $-O-C_1-C_6$ alkyl, $-NH(C_1-C_6$ alkyl), or $-N(C_1-C_6$ alkyl) $_2$,
n is an integer from 0 to 3;


R₁₀ is selected from the group of H, halogen, -CF₃, -OH, -(CH₂)_n-COOH, -(CH₂)_n-C(O)-COOH, -C₁-C₆ alkyl, -O-C₁-C₆ alkyl, -NH(C₁-C₆ alkyl), -N(C₁-C₆ alkyl)₂,



R₁₁ is selected from H, C₁-C₆ lower alkyl, C₁-C₆ cycloalkyl, -CF₃, -COOH, -(CH₂)_n-COOH, -(CH₂)_n-C(O)-COOH,



with a proviso that the complete moiety at the indole or indoline 1-position created by any combination of R_5 , R_8 , R_9 , R_{10} , and/or R_{11} shall contain at least one acidic moiety selected from or containing a carboxylic acid, a tetrazole, or a moiety of the formulae: $-C(O)NH_2$, $-(CH_2)_n-C(O)NH_2$,



n is an integer from 0 to 3;
or a pharmaceutically acceptable salt thereof.

2 (Amended). A compound of Claim 1 wherein:

R_1 and $R_{1'}$ are independently selected from H, halogen, $-CF_3$, $-OH$, $-C_1-C_{10}$ alkyl, $-S-C_1-C_{10}$ alkyl, C_1-C_{10} alkoxy, $-CN$, $-NO_2$, $-NH_2$, $-HN(C_1-C_6)$, $-N(C_1-C_6)_2$, phenyl, $-O$ -phenyl, $-S$ -phenyl, benzyl, $-O$ -benzyl, or $-S$ -benzyl, the phenyl and benzyl rings of these groups being optionally substituted by from 1 to 3 substituents selected from halogen, C_1-C_6 alkyl, C_1-C_6 alkoxy, $-NO_2$, $-NH_2$, $-CN$, $-CF_3$, or $-OH$;

M^1 is selected from: H, C_1-C_6 lower alkyl, C_1-C_6 lower alkoxy, C_3-C_{10} cycloalkyl, phenyl or benzyl, the cycloalkyl, phenyl or benzyl rings being optionally substituted by from 1 to 3 substituents selected from halogen, C_1-C_{10} alkyl, C_1-C_{10} alkoxy, $-NO_2$, $-NH_2$, $-CN$, or $-CF_3$;

R_4 is a moiety of the formulae $-(CH_2)_n-A$, $-(CH_2)_n-S-A$, or $-(CH_2)_n-O-A$, wherein A is the moiety:



wherein

D is H, C₁-C₆ lower alkyl, C₁-C₆ lower alkoxy, or -CF₃;

B and C are independently selected from phenyl, pyridinyl, furyl, thienyl, pyrimidinyl or pyrrolyl groups, each optionally substituted by from 1 to 3 substituents selected from H, halogen, -CF₃, -OH, -C₁-C₆ alkyl, C₁-C₆ alkoxy, or -NO₂; or a pharmaceutically acceptable salt thereof.

3 (Amended). A compound of Claim 2 wherein R₄ is the moiety:



B and C are phenyl optionally substituted by from 1 to 3 substituents selected from H, halogen, -CF₃, -OH, -C₁-C₆ alkyl, C₁-C₆ alkoxy, or -NO₂; and R₁, R_{1'}, R₂, R₃, R₅, L¹, M¹ and D are as defined in Claim 2; or a pharmaceutically acceptable salt thereof.

4 (Amended). A compound of Claim 1 wherein:

R₄ is selected from the group of C₁-C₆ lower alkyl, C₁-C₆ lower alkoxy, -(CH₂)_n-C₃-C₆ cycloalkyl, -(CH₂)_n-S-(CH₂)_n-C₃-C₆ cycloalkyl, -(CH₂)_n-O-(CH₂)_n-C₃-C₆ cycloalkyl, or the groups of:

a) a moiety of the formulae -(CH₂)_n-A, -(CH₂)_n-S-A, or -(CH₂)_n-O-A, wherein A is the moiety:




wherein

D is H, C₁-C₆ lower alkyl, C₁-C₆ lower alkoxy, or -CF₃;

B and C are independently selected from phenyl, pyridinyl, furyl, thienyl, pyrimidinyl or pyrrolyl groups, each optionally substituted by from 1 to 3, substituents selected from H, halogen, -CF₃, -OH, -C₁-C₆ alkyl, C₁-C₆ alkoxy, or -NO₂; or

b) a moiety of the formula -L²-M², wherein L² and M² are as defined in claim 1;

R_5 is selected from $-\text{COOH}$, $-\text{C}(\text{O})-\text{COOH}$, $-(\text{CH}_2)_n-\text{C}(\text{O})-\text{COOH}$, $-(\text{CH}_2)_n-\text{COOH}$, $(\text{CH}_2)_n-\text{CH}=\text{CH}-\text{COOH}$, $-(\text{CH}_2)_n$ -tetrazole, $-\text{CH}_2$ -phenyl- $\text{C}(\text{O})$ -benzothiazole, or



or a moiety selected from the formulae $-\text{L}^3-\text{M}^3$ wherein L^3 and M^3 are as defined in claim 1;
or a pharmaceutically acceptable salt thereof.

5 (Amended). A compound of Claim 1 wherein:

$R_{1'}$ is H;

R_4 is selected from the group of C_1-C_6 lower alkyl, C_1-C_6 lower alkoxy, $-(\text{CH}_2)_n-\text{C}_3-\text{C}_6$ cycloalkyl, $-(\text{CH}_2)_n-\text{S}-(\text{CH}_2)_n-\text{C}_3-\text{C}_5$ cycloalkyl, $-(\text{CH}_2)_n-\text{O}-(\text{CH}_2)_n-\text{C}_3-\text{C}_5$ cycloalkyl, or a moiety of the formulae $-(\text{CH}_2)_n-\text{A}$, $-(\text{CH}_2)_n-\text{S}-\text{A}$, or $-(\text{CH}_2)_n-\text{O}-\text{A}$, wherein A is the moiety:




wherein

D is H, C_1-C_6 lower alkyl, C_1-C_6 lower alkoxy, or $-\text{CF}_3$;

B and C are independently selected from phenyl, pyridinyl, furyl, thienyl, pyrimidinyl or pyrrolyl groups, each optionally substituted by from 1 to 3, substituents selected from H, halogen, $-\text{CF}_3$, $-\text{OH}$, C_1-C_6 alkyl, C_1-C_6 alkoxy, or $-\text{NO}_2$;


R_5 is selected from $-\text{COOH}$, $-\text{C}(\text{O})-\text{COOH}$, $-(\text{CH}_2)_n-\text{C}(\text{O})-\text{COOH}$, $-(\text{CH}_2)_n-\text{COOH}$, $(\text{CH}_2)_n-\text{CH}=\text{CH}-\text{COOH}$, $-(\text{CH}_2)_n$ -tetrazole, or



or a moiety selected from the formulae $-\text{L}^3-\text{M}^3$;


wherein L^3 is a bridging or linking moiety selected from a chemical bond, $-(\text{CH}_2)_n-$, $-\text{SO}_2-$, $-\text{C}(\text{O})-$, $-(\text{CH}_2)_n-\text{C}(\text{O})-$, $-(\text{CH}_2)_n-\text{C}(\text{O})-(\text{CH}_2)_n-$, $-(\text{CH}_2)_n-\text{O}-(\text{CH}_2)_n-$, $-(\text{CH}_2)_n-\text{S}-(\text{CH}_2)_n-$, $-(\text{CH}_2)_n-\text{SO}-(\text{CH}_2)_n-$, $-(\text{CH}_2)_n-\text{SO}_2-(\text{CH}_2)_n-$, or $-(\text{CH}_2)_n-\text{CH}=\text{CH}-(\text{CH}_2)_n-\text{O}-$;

M^3 is selected from the group of $-\text{COOH}$, $-(\text{CH}_2)_n-\text{COOH}$, $-(\text{CH}_2)_n-\text{C}(\text{O})-\text{COOH}$, tetrazole,



where R_8 , R_9 can be attached anywhere in the cyclic or bicyclic system,
 n is an integer from 0 to 3;


R_8 , in each appearance, is independently selected from H, $-\text{COOH}$, $-(\text{CH}_2)_n-\text{COOH}$, $-(\text{CH}_2)_n-\text{C}(\text{O})-\text{COOH}$, tetrazole, $-\text{C}(\text{O})-\text{NH}_2$, $-(\text{CH}_2)_n-\text{C}(\text{O})-\text{NH}_2$,



n is an integer from 0 to 3;

R_8 is selected from H, halogen, $-CF_3$, $-OH$, $-COOH$, $-(CH_2)_n-COOH$,
 $-(CH_2)_n-C(O)-COOH$, $-C_1-C_6$ alkyl, $-O-C_1-C_6$ alkyl, $-NH(C_1-C_6 \text{ alkyl})$, or $-N(C_1-C_6 \text{ alkyl})_2$;
 n is an integer from 0 to 3;

with a proviso that the complete moiety at the indole or indoline 1-position
 created by any combination of R_5 , R_8 , R_9 , shall contain at least one acidic moiety selected
 from or containing a carboxylic acid, a tetrazole, or a moiety of the formulae: $-C(O)-NH_2$, $-$
 $(CH_2)_n-C(O)-NH_2$,




n is an integer from 0 to 3;
 or a pharmaceutically acceptable salt thereof.

6 (Amended). A compound of Claim 1 wherein:

R_1 is selected from H, halogen, $-CF_3$, $-OH$, $-C_1-C_{10}$ alkyl, $-S-C_1-C_{10}$ alkyl, C_1-C_{10}
 alkoxy, $-CN$, $-NO_2$, $-NH_2$, $-HN(C_1-C_6)$, $-N(C_1-C_6)_2$, phenyl, $-O$ -phenyl, $-S$ -phenyl, benzyl, $-O$ -
 benzyl, $-S$ -benzyl, the phenyl and benzyl rings of these groups being optionally substituted
 by from 1 to 3 substituents selected from halogen, C_1-C_6 alkyl, C_1-C_6 alkoxy, $-NO_2$, $-NH_2$, $-$
 CN , $-CF_3$, or $-OH$;

or R_1 and R_1' are independently a moiety of the formulae:
 or a moiety of the formulae:



R_6 and R_7 are as defined in claim 1;

R_3 is selected from H, $-CF_3$, C_1-C_6 lower alkyl, C_1-C_6 lower alkoxy, C_3-C_{10} cycloalkyl, $-C_1-C_6$ alkyl, $-C_3-C_{10}$ cycloalkyl, $-CHO$, halogen, $(CH_2)_n C(O)NH_2$ or a moiety of the formula $-L^1-M^1$:

L^1 indicates a linking or bridging group of the formulae $-(CH_2)_n-$, $-C(O)-$, $-(CH_2)_n-C(O)-$, $-(CH_2)_n-C(O)-(CH_2)_n-$, $-(CH_2)_n-O-(CH_2)_n-$, or $-(CH_2)_n-S-(CH_2)_n-$, $C(O)C(O)X$, $-(CH_2)_n-N-(CH_2)_n-$;

M^1 is selected from H, the group of C_1-C_6 lower alkyl, C_1-C_6 lower alkoxy, C_3-C_{10} cycloalkyl, phenyl or benzyl, the cycloalkyl, phenyl or benzyl rings being optionally substituted by from 1 to 3 substituents selected from halogen, C_1-C_{10} alkyl, C_1-C_{10} alkoxy, $-NO_2$, $-NH_2$, $-CN$, or $-CF_3$;

R_4 is selected from the group of C_1-C_6 lower alkyl, C_1-C_6 lower alkoxy, $-(CH_2)_n-C_3-C_6$ cycloalkyl, $-(CH_2)_n-S-(CH_2)_n-C_3-C_5$ cycloalkyl, $-(CH_2)_n-O-(CH_2)_n-C_3-C_5$ cycloalkyl, or a moiety of the formulae $-(CH_2)_n-A$, $-(CH_2)_n-S-A$, or $-(CH_2)_n-O-A$, wherein A is the moiety:




wherein

D is H, C_1-C_6 lower alkyl, C_1-C_6 lower alkoxy, or $-CF_3$;

B and C are independently selected from phenyl, pyridinyl, furyl, thienyl, pyrimidinyl or pyrrolyl groups, each optionally substituted by from 1 to 3, substituents selected from H, halogen, $-CF_3$, $-OH$, $-C_1-C_6$ alkyl, C_1-C_6 alkoxy, or $-NO_2$;


R_5 is selected from $-COOH$, $-C(O)-COOH$, $-(CH_2)_n-C(O)-COOH$, $-(CH_2)_n-COOH$, $(CH_2)_n-CH=CH-COOH$, $-(CH_2)_n$ -tetrazole, or a moiety selected from the formulae $-L^3-M^3$; wherein L^3 is a bridging or linking moiety selected from a chemical bond, $-(CH_2)_n-$, $-(CH_2)_n-C(O)-(CH_2)_n-$, $-(CH_2)_n-O-(CH_2)_n-$, $-(CH_2)_n-S-(CH_2)_n-$, $-(CH_2)_n-SO-(CH_2)_n-$, $-(CH_2)_n-SO_2-(CH_2)_n-$, or $-(CH_2)_n-CH=CH-(CH_2)_n-$;

M^3 is selected from the group of $-COOH$, $-(CH_2)_n-COOH$, $-(CH_2)_n-C(O)-COOH$, tetrazole,



where R_8, R_9 can be attached anywhere in the cyclic or bicyclic system,
 n is an integer from 0 to 3;

R_8 , in each appearance, is independently selected from H, $-\text{COOH}$, $-(\text{CH}_2)_n-\text{COOH}$, $-(\text{CH}_2)_n-\text{C}(\text{O})-\text{COOH}$, tetrazole, $-\text{C}(\text{O})-\text{NH}_2$, $-(\text{CH}_2)_n-\text{C}(\text{O})-\text{NH}_2$,




n is an integer from 0 to 3;

R_9 is selected from H, halogen, $-\text{CF}_3$, $-\text{OH}$, $-\text{COOH}$, $-(\text{CH}_2)_n-\text{COOH}$, $-(\text{CH}_2)_n-\text{C}(\text{O})-\text{COOH}$, $-\text{C}_1-\text{C}_8$ alkyl, $-\text{O}-\text{C}_1-\text{C}_8$ alkyl, $-\text{NH}(\text{C}_1-\text{C}_8 \text{ alkyl})$, or $-\text{N}(\text{C}_1-\text{C}_8 \text{ alkyl})_2$;

n an integer from 0 to 3;

with a proviso that the complete moiety at the indole or indoline 1-position created by any combination of R_5, R_6, R_9 , shall contain at least one acidic moiety selected from or containing a carboxylic acid, a tetrazole, or a moiety of the formulae: $-\text{C}(\text{O})-\text{NH}_2$, $-(\text{CH}_2)_n-\text{C}(\text{O})-\text{NH}_2$.



n is an integer from 0 to 3;

or a pharmaceutically acceptable salt thereof.

7 (Amended). A compound of Claim 1 wherein:

R_7 is selected from -OH, -CF₃, C₁-C₆ alkyl, C₁-C₆ alkoxy, -NH-(C₁-C₆ alkyl), -N-(C₁-C₆ alkyl)₂, pyridinyl, thienyl, furyl, pyrrolyl, phenyl, -O-phenyl, benzyl, -O-benzyl, the rings of these groups being optionally substituted by from 1 to 3 substituents selected from halogen, -CN, C₁-C₆ alkyl, C₁-C₆ alkoxy, -NO₂, -NH₂, -CF₃, or -OH;

R_3 is selected from H, -C₁-C₁₀ alkyl, -(CH₂)_n-OH, (CH₂)_nC(O)NH₂, -CH₂-O-(C₁-C₆ alkyl, -CH₂-O-CH₂-phenyl, -CH₂-N-(C₁-C₆ alkyl), -CH₂-N-CH₂-phenyl, the phenyl rings of which are optionally substituted by 1 or 2 groups selected from H, halogen, -CF₃ or -C₁-C₆ alkyl;

Alt
Ent
X is O or N

n = 0 or 1;

R_4 is a moiety of the formulae -(CH₂)_n-A, -(CH₂)_n-S-A, or -(CH₂)_n-O-A, wherein A is the moiety:




wherein

D is H, C₁-C₆ lower alkyl, C₁-C₆ lower alkoxy, or -CF₃;

B and C are independently selected from phenyl, pyridinyl, furyl, thienyl or pyrrolyl groups, each optionally substituted by from 1 to 3, substituents selected from H, halogen, -CF₃, -OH, -C₁-C₆ alkyl, C₁-C₆ alkoxy, or -NO₂;

R_5 is a moiety selected from the groups of:




wherein L^1 is a bridging or linking moiety selected from a chemical bond, $-(CH_2)_n$, $-(CH_2)_n$ -C(O)- $(CH_2)_n$, $-(CH_2)_n$ -O- $(CH_2)_n$, $-(CH_2)_n$ -S- $(CH_2)_n$, $-(CH_2)_n$ -SO- $(CH_2)_n$, $-(CH_2)_n$ -SO₂- $(CH_2)_n$, or $-(CH_2)_n$ -CH=CH- $(CH_2)_n$ -O-;

where n is an integer from 0 to 5;

R_9 is selected from $-CF_3$, $-C_1-C_6$ alkyl, C_1-C_6 alkoxy, $-NH(C_1-C_6 \text{ alkyl})$, or $-N(C_1-C_6 \text{ alkyl})_2$.

n in each instance is independently selected as an integer from 0 to 3;
or a pharmaceutically acceptable salt thereof.

8 (Amended). A compound of Claim 1 having the formulae:



wherein:

R_1 is selected from H, halogen, $-\text{CF}_3$, $-\text{OH}$, $-\text{C}_1\text{-C}_{10}$ alkyl, $-\text{S-C}_1\text{-C}_{10}$ alkyl, $\text{C}_1\text{-C}_{10}$ alkoxy, $-\text{CN}$, $-\text{NO}_2$, $-\text{NH}_2$, $-\text{HN}(\text{C}_1\text{-C}_6)$, $-\text{N}(\text{C}_1\text{-C}_6)_2$, phenyl, $-\text{O-phenyl}$, $-\text{S-phenyl}$, benzyl, $-\text{O-benzyl}$, $-\text{S-benzyl}$, the phenyl and benzyl rings of these groups being optionally substituted by from 1 to 3 substituents selected from halogen, $\text{C}_1\text{-C}_6$ alkyl, $\text{C}_1\text{-C}_6$ alkoxy, $-\text{NO}_2$, $-\text{NH}_2$, $-\text{CN}$, $-\text{CF}_3$, or $-\text{OH}$;

Al
cont
 R_2 is selected from H, halogen, $-\text{CF}_3$, $-\text{OH}$, $-\text{C}_1\text{-C}_{10}$ alkyl, $\text{C}_1\text{-C}_{10}$ alkoxy, $-\text{CHO}$, $-\text{CN}$, $-\text{NO}_2$, $-\text{NH}_2$, $-\text{NH-C}_1\text{-C}_6$ alkyl, $-\text{N}(\text{C}_1\text{-C}_6 \text{ alkyl})_2$, $-\text{N-SO}_2\text{-C}_1\text{-C}_6$ alkyl, or $-\text{SO}_2\text{-C}_1\text{-C}_6$ alkyl;

R_3 is selected from H, $-\text{C}_1\text{-C}_{10}$ alkyl, $-(\text{CH}_2)\text{-OH}$, $(\text{CH}_2)_n\text{C}(\text{O})\text{NH}_2$, $-\text{CH}_2\text{-O-}(\text{C}_1\text{-C}_6 \text{ alkyl})$, $-\text{CH}_2\text{-O-CH}_2\text{-phenyl}$, $-\text{CH}_2\text{-N-}(\text{C}_1\text{-C}_6 \text{ alkyl})$, $-\text{CH}_2\text{-N-CH}_2\text{-phenyl}$, the phenyl rings of which are optionally substituted by 1 or 2 groups selected from H, halogen, $-\text{CF}_3$ or $-\text{C}_1\text{-C}_6$ alkyl;

$n = 0$ or 1 .

R_4 is a moiety of the formulae $-(\text{CH}_2)_n\text{-A}$, $-(\text{CH}_2)_n\text{-S-A}$, or $-(\text{CH}_2)_n\text{-O-A}$, wherein A is the moiety:




wherein

D is H, $\text{C}_1\text{-C}_6$ lower alkyl, $\text{C}_1\text{-C}_6$ lower alkoxy, or $-\text{CF}_3$;

B and C are independently selected from phenyl, pyridinyl, furyl, thienyl or pyrrolyl groups, each optionally substituted by from 1 to 3, substituents selected from H, halogen, $-\text{CF}_3$, $-\text{OH}$, $-\text{C}_1\text{-C}_6$ alkyl, $\text{C}_1\text{-C}_6$ alkoxy, or $-\text{NO}_2$;

R_5 is a moiety selected from the groups of:




wherein L^1 is a bridging or linking moiety selected from a chemical bond, $-(CH_2)_n$, $-(CH_2)_n-C(O)-(CH_2)_n$, $-(CH_2)_n-O-(CH_2)_n$, $-(CH_2)_n-S-(CH_2)_n$, $-(CH_2)_n-SO-(CH_2)_n$, $-(CH_2)_n-SO_2-(CH_2)_n$, or $-(CH_2)_n-CH=CH-(CH_2)_n-O$;

where $n = 0-5$

R_9 is selected from $-CF_3$, $-C_1-C_6$ alkyl, C_1-C_6 alkoxy, $-NH(C_1-C_6 \text{ alkyl})$, or $-N(C_1-C_6 \text{ alkyl})_2$,

n in each instance is independently selected as an integer from 0 to 3, or a pharmaceutically acceptable salt thereof.

9 (Amended). A compound of Claim 1 having the formulae:



wherein:


R_1 is selected from H, halogen, $-CF_3$, $-OH$, $-CN$, $-NO_2$, $-NH_2$, $-HN(C_1-C_6)$, $-N(C_1-C_6)_2$, phenyl, $-N-SO_2-C_1-C_6$ alkyl, or $-SO_2-C_1-C_6$ alkyl;

R₂ is selected from H, halogen, -CF₃, -OH, , -CN, -NO₂, -NH₂, -NH-C₁-C₆ alkyl, -N(C₁-C₆ alkyl)₂, -N-SO₂-C₁-C₆ alkyl, or -SO₂-C₁-C₆ alkyl;

R₃ is selected from H, -C₁-C₁₀ alkyl, -(CH₂)_n-OH, (CH₂)_n-C(O)NH₂, -CH₂-O-(C₁-C₆ alkyl), -CH₂-O-CH₂-phenyl, -CH₂-N-(C₁-C₆ alkyl), -CH₂-N-CH₂-phenyl, the phenyl rings of which are optionally substituted by 1 or 2 groups selected from H, halogen, -CF₃ or -C₁-C₆ alkyl;

n = 0 or 1.

R₅ is a moiety selected from the groups of:



wherein L¹ is a bridging or linking moiety selected from a chemical bond, -(CH₂)_n-, -(CH₂)_n-C(O)-(CH₂)_n-, -(CH₂)_n-O-(CH₂)_n-, -(CH₂)_n-S-(CH₂)_n-, -(CH₂)_n-SO-(CH₂)_n-, -(CH₂)_n-SO₂-(CH₂)_n-, or -(CH₂)_n-CH=CH-(CH₂)_n-O-;

n' in each instance is independently selected as an integer from 0 to 5;
or a pharmaceutically acceptable salt thereof.

REMARKS

Claims 1-20 are pending. Although the Office Action Summary states that claims 10-15 have been allowed, claims 1, 5-7 and 20 have been rejected, and claims 1-9 and 16-20 have been objected to, in the office action it appears that all 20 claims have been rejected and claims 1-9 and 16-20 have been objected to. Reconsideration of the application in view of the amendments and remarks contained herein is respectfully requested.

The Examiner has repeated the requirement to elect a species and has stated that the claims will be "examined to the extent they read on R5 is L3 and M3 is